A revision of the conflict of interest policy for JAMA will help ensure complete disclosure and transparency in regard to this matter

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1546, 2006-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Meta-Analyses and Conflict of Interest

By Fava Giovanni A.  

CNS Drugs, Vol. 26, Iss. 2, 2012-02 ,pp. : 93-96

Adis International

Access to resources Recommend Favorite

Conflict of Interest and Oncology Guidelines

By Burstein Harold J.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 955-955

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Prescribing and dispensing in Japan: conflict of interest?

By Tatara Kozo  

Clinical Medicine, Vol. 3, Iss. 6, 2003-11 ,pp. : 555-555

Royal College Of Physicians

Access to resources Recommend Favorite

Public Disclosure of Clinical Trial Results: A Necessary Step on the Path to Transparency and Trust

By Rockhold Frank W.  

Pharmaceutical Medicine, Vol. 23, Iss. 3, 2009-06 ,pp. : 131-137

Adis International

Access to resources Recommend Favorite

Conflict-of-interest policies protect docs from big pharma influence

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 671, 2013-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite